Olanzapine And Fluoxetine Capsule
Product Images NDC 42291-652

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Olanzapine And Fluoxetine (NDC 42291-652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label 4229165230 3mg 25mg 2014

Label 4229165230 3mg 25mg 2014
FDA Label Image

Label 4229165330 6mg 25mg 2013

Label 4229165330 6mg 25mg 2013
FDA Label Image

Label 4229165430 6mg 50mg 2013

Label 4229165430 6mg 50mg 2013
FDA Label Image

Label 4229165530 12mg 25mg 2018

Label 4229165530 12mg 25mg 2018
FDA Label Image

Label 4229165630 12mg 50mg 2013

Label 4229165630 12mg 50mg 2013
FDA Label Image

Olanzapine And Fluoxetine Capsules 1

Olanzapine And Fluoxetine Capsules 1
FDA Label Image

Olanzapine And Fluoxetine Capsules 2

Olanzapine And Fluoxetine Capsules 2
The description is: "Fluoxetine Hydrochloride".*
FDA Label Image

Olanzapine And Fluoxetine Capsules 3

Olanzapine And Fluoxetine Capsules 3
This is a chart showing the proportion of patients with relapse over time after randomization to receive olanzapine or fluoxetine and floxetine treatment. The x-axis represents the time in days from randomization to relapse and the y-axis shows the proportion of patients with relapse. The chart suggests that the olanzapine treatment group had a lower proportion of patients with relapse compared to the fluoxetine and floxetine treatment group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.